Boothbay Fund Management’s Bellevue Life Sciences Acquisition Corp. Rights BLACR Stock Holding History

Boothbay Fund Management’s Portfolio BLACR Stock Details BLACR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-311,040	Closed	-$41.8K	–	1893
2024 Q4	$41.8K	Hold	311,040	–	–	﹤0.01%	1373
2024 Q3	$36.4K	Hold	311,040	–	–	﹤0.01%	1529
2024 Q2	$37.5K	Hold	311,040	–	–	﹤0.01%	1430
2024 Q1	$44.5K	Hold	311,040	–	–	﹤0.01%	1480
2023 Q4	$46.6K	Hold	311,040	–	–	﹤0.01%	1532
2023 Q3	$71.5K	Hold	311,040	–	–	﹤0.01%	1601
2023 Q2	$59.5K	Hold	311,040	–	–	﹤0.01%	1667
2023 Q1	$51.3K	Buy	+311,040	New	+$48.3K	﹤0.01%	2016

Boothbay Fund Management's BLACR Position: Q1 2025 in Review

Boothbay Fund Management sold out of Bellevue Life Sciences Acquisition Corp. Rights (BLACR) in Q1 2025, closing a stake of 311,040 shares — an estimated $41.8K sold.

Boothbay Fund Management first reported a position in BLACR in Q1 2023 and held it in 8 quarters. The position peaked at $71.5K in Q3 2023. 0 funds tracked by Wall St. Rank hold BLACR as of Q1 2025.

Boothbay Fund Management reported no remaining Bellevue Life Sciences Acquisition Corp. Rights position as of Q1 2025 after selling out during the quarter.
Boothbay Fund Management sold 311,040 Bellevue Life Sciences Acquisition Corp. Rights shares in Q1 2025, an estimated $41.8K.
Boothbay Fund Management first reported a position in Bellevue Life Sciences Acquisition Corp. Rights in Q1 2023 and held it in 8 quarters.
Boothbay Fund Management's Bellevue Life Sciences Acquisition Corp. Rights position peaked at $71.5K in Q3 2023.
0 funds tracked by Wall St. Rank held Bellevue Life Sciences Acquisition Corp. Rights as of Q1 2025.

Based on Boothbay Fund Management's 13F filing for Q1 2025, filed 15 May 2025.